title: [Signaling pathways that control the growth and survival of prostate tumor cells in the absence of androgens].
abstract: Androgen-dependent human prostate adenocarcinoma cell line LNCaP was used to study the effect of androgen deprivation on the cell response to TNF-related cytokines. Several signaling pathways were implicated in cell survival in the absence of androgens. In androgen-deprived LNCaP cells, TNF-alpha and TRAIL stimulated the cell growth and activated the mitogenic and antiapoptotic signaling pathways involving NF-kappa B, STAT3, PI3K, and beta-catenin. The results suggested a role of cytokines in the survival of prostate adenocarcinoma cells deprived of androgens in vitro.
authors.affiliation: Q-RNA, New York, NY 10032, USA. vadler@q-rna.com
authors.forename: V V
authors.initials: VV
authors.lastname: Adler
authors.forename: A V
authors.initials: AV
authors.lastname: Polotskaia
authors.forename: E S
authors.initials: ES
authors.lastname: Gershteĭn
authors.forename: M A
authors.initials: MA
authors.lastname: Krasil'nikov
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology; D000728:Androgens / Q000378:metabolism*; D000730:Androstadienes / Q000494:pharmacology; D051017:Apoptosis Regulatory Proteins; D002455:Cell Division / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D016207:Cytokines / Q000378:metabolism / Q000494:pharmacology; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D003598:Cytoskeletal Proteins / Q000187:drug effects / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D006801:Humans; D051821:Lymphoid Enhancer-Binding Factor 1; D008297:Male; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000187:drug effects / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D050796:STAT3 Transcription Factor; D015398:Signal Transduction; D053221:TNF-Related Apoptosis-Inducing Ligand; D013936:Thymidine / Q000378:metabolism; D015534:Trans-Activators / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000378:metabolism / Q000494:pharmacology; D000077191:Wortmannin; D051176:beta Catenin
chemical_list: D000111:Acetylcysteine; D000728:Androgens; D000730:Androstadienes; D051017:Apoptosis Regulatory Proteins; D016207:Cytokines; D003598:Cytoskeletal Proteins; D004268:DNA-Binding Proteins; D051821:Lymphoid Enhancer-Binding Factor 1; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D050796:STAT3 Transcription Factor; D053221:TNF-Related Apoptosis-Inducing Ligand; D013936:Thymidine; D015534:Trans-Activators; D014157:Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D000077191:Wortmannin; D051176:beta Catenin; C495270:CTNNB1 protein, human; C494086:STAT3 protein, human; C505653:TNFSF10 protein, human